Table 1.

Baseline Characteristics

Baseline characteristics	CD (n = 36)	UC (n = 10)	Total (N = 46)
Female	18 (50)	5 (50)	23 (50)
Age, y	42 (27–53)	52 (36–61)	44 (27–56)
Disease duration, y	11 (6–20)	13 (7–22)	12 (7–21)
Ethnic background
Caucasian	30 (83.3)	9 (90)	39 (84.8)
Disease location CD
Ileal disease (L1)	14 (38.9)	–	14 (38.9)
Colonic disease (L2)	4 (11.1)	–	4 (11.1)
Ileocolonic disease (L3)	18 (50)	–	18 (50)
Disease location UC
Left-sided UC, distal to splenic flexure (E2)		3 (30)	3 (30)
Extensive, proximal to splenic flexure (E3)		7 (70)	7 (70)
Disease behavior
Non-stricturing/penetrating (B1)	9 (25)	–	9 (25)
Stricturing (B2)	13 (36.1)	–	13 (36.1)
Penetrating (B3)	14 (38.9)	–	14 (38.9)
Perianal disease (p)	12 (36.1)	–	12 (36.1)
Previous IBD-related surgery	19 (52.8)	1 (10)	20 (43.5)
IBD-related surgery between T1 and T2	10 (27.8)	–	10 (21.7)
Previous medical treatment
Immunomodulator (AZA, 6MP, 6TG, MTX)	29 (80.6)	7 (70)	36 (78.3)
Anti-TNF (IFX and/or ADA)	28 (77.8)	4 (40)	32 (69.6)
Ustekinumab	1 (2.8)	–	1 (2.2)
Treatment between T1 and T2
Immunomodulator (AZA, 6MP, 6TG, MTX)	14 (38.9)	3 (30)	17 (37)
Anti-TNF (IFX and/or ADA)	16 (44.4)	7 (70)	23 (50)
Vedolizumab	17 (47.2)	7 (70)	24 (52.2)
Ustekinumab	13 (36.1)	1 (10)	14 (30.4)
CRP T1, mg/L	3.2 (1.4–8.0)	2 (0.4–5.8)	2.6 (1.2–6.6)
CRP T2, mg/L	3 (1.6–5.3)	2.5 (0.8–7.7)	3.0 (1.4–5.3)
Leukocyte count T1, ∗10ˆ9	7.1 (6.3–9.1)	5.4 (4.7–6.3)	6.7 (5.4–8.3)
Leukocyte count T2, ∗10ˆ9	7.1 (5.7–8.9)	5.8 (5.2–7.6)	7.1 (5.3–8.5)
Smoking
Active	8 (22.2)	3 (30)	11 (23.9)
Non-smoker	28 (77.8)	7 (70)	35 (76.1)

Note: Data are presented as number (%) or median (interquartile range).

CD, Crohn’s disease; CRP, C-reactive protein; IBD, inflammatory bowel disease; UC, ulcerative colitis.